Company intelligence / Profile preview

Harmony BioDesign

Plymouth Meeting, Pennsylvania, United Statesbiodesignfoundation.org ↗

Ownership: Private
Employees: ~180
Development stage: Other

Overview

The company has a robust late-stage pipeline with multiple programs in development, including pitolisant for idiopathic hypersomnia and a pitolisant-HD development program. They also have BP1.15205, described as a potential best-in-class orexin-2 agonist, and two products (ZYN002 and EPX100) in registrational Phase 3 trials[2][6].

Therapeutic areas: Neurology
Modalities: Small molecules (pitolisant)orexin-2 agonist (BP1.15205)
Industry: Biotech

Beyond the preview

Go deeper on Harmony BioDesign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harmony BioDesign.

Explore the full profile